CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors
09 sept. 2024 08h00 HE
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today...
CytomX Therapeutics to Present at Upcoming September Investor Conferences
04 sept. 2024 08h00 HE
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that...
CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
08 août 2024 16h10 HE
|
CytomX Therapeutics Inc.
- CX-904 (EGFR-CD3 PROBODY® T-cell engager) Phase 1a enrollment continues, primarily focused in PDAC, NSCLC, and HNSCC. Program update expected by the end of 2024 - - Phase 1 clinical study of...
CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024
01 août 2024 08h00 HE
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today...
CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
18 juin 2024 08h00 HE
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today...
CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer
17 juin 2024 16h15 HE
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the...
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
22 mai 2024 16h05 HE
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today...
CytomX Therapeutics Announces New Employment Inducement Grants
16 mai 2024 16h15 HE
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that on...
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)
08 mai 2024 16h10 HE
|
CytomX Therapeutics Inc.
- CX-904 demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall - - Encouraging initial...
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
08 mai 2024 16h10 HE
|
CytomX Therapeutics Inc.
- Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors - - First dose cohort cleared in Phase 1 clinical study of CX-2051,...